Abstract
The prevalence of allergic diseases among infants is increasing particularly in developed countries. Although, the exact reason is not clear yet, one of the most probable explanations is reducing microbial exposure during early life and consequent alteration of gut microbiota. Various factors including delivery mode, infant`s diet, environment and antibiotics administration by mothers are involved in microbial colonization of infant`s intestine. Since the content of infant`gut microbiota plays a critical role in the maturation and development of the immune system, it determines the risk of immune diseases. Different studies confirmed the important role of vaginal delivery, due to transferring of useful bacteria to the neonatal’s intestine, and breastfeeding, owing to the presence of exosomes and different kind of mediators in the milk which modify the pattern of intestinal microflora. As a result, it was proposed that both factors have remarkable effects on reducing allergic diseases. Furthermore, the consumption of probiotic productions by the mother during and after pregnancy possibly induces beneficial impacts on attenuating the allergic diseases.
Keywords: Allergic diseases, breast milk, cesarean, delivery, exosome, probiotic.
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Current Medicinal Chemistry
Current Pharmaceutical Biotechnology
Central Nervous System Agents in Medicinal Chemistry
Letters in Drug Design & Discovery
Current Drug Discovery Technologies
Recent Advances in Anti-Infective Drug Discovery
Related Books
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part II
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I
Frontiers in Cardiovascular Drug Discovery
Frontiers in Drug Design and Discovery
Frontiers in Anti-Cancer Drug Discovery
Frontiers in Drug Design and Discovery
Anti-Obesity Drug Discovery and Development
44